Eskander, R.N. and Randall, L.M. (2011) Bevacizumab in the Treatment of Ovarian Cancer. Biologics Targets & Therapy, 5, 1-5. - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

Eskander, R.N. and Randall, L.M. (2011) Bevacizumab in the Treatment of Ovarian Cancer. Biologics: Targets & Therapy, 5, 1-5.

has been cited by the following article:

TITLE: Current Possible Drug Therapies for Ovarian Cancer

AUTHORS: Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim

KEYWORDS: Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy

JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.13, November 7, 2014

ABSTRACT: Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cytoreductive therapy followed by molecular targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is a hot therapeutic concept in ovarian cancers. In our review, we will introduce recent therapeutic advances in epithelial ovarian cancer patients.

Open Access

The 2-Series Eicosanoids in Cancer: Future Targets for Glioma Therapy?

Tiberiu Moga, Sunit Das

DOI: 10.4236/jct.2013.41041 4,322 Downloads 6,729 Views Citations

Pub. Date: February 27, 2013

Open Access

Dermatomyositis Associated with Docetaxel Use in the Treatment for Ovarian Cancer

Yuta Ito, Yuko Hamada, Keiko Katayama, Hirokazu Uno, Tokio Nakada

DOI: 10.4236/crcm.2017.610031 570 Downloads 958 Views Citations

Pub. Date: October 23, 2017

Open Access

Clinical Analysis of Bevacizumab Plus FOLFIRI Regimen as Front-Line Therapy for Chinese Patients with Advanced Colorectal Cancer

Xijian Zhou, Jun Yang, Jinying Liang, Peng Li, Yuquan Wu, Xiaoqiang Fan, Xiangyong Li

DOI: 10.4236/jct.2011.24063 4,577 Downloads 7,647 Views Citations

Pub. Date: October 12, 2011

Open Access

Retrospective Analysis of S-1 plus Bevacizumab as Maintenance Therapy after Induction of S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer

Yasutake Uchima, Naoki Aomatsu, Gen Tsujio, Takehiko Iwauchi, Shinji Matsutani, Hiroto Tanaka, Hironari Miyamoto, Takuma Okada, Shigeaki Kurihara, Toshiki Hirakawa, Keiichiro Hirata, Junya Morimoto, Shigehito Yamagata, Kazuhiro Takeuchi

DOI: 10.4236/jct.2020.112004 630 Downloads 1,286 Views Citations

Pub. Date: January 22, 2020

Open Access

Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Guillermo López Vivanco, Eider Azkona, Sergio Carrera, Aintzane Sancho, Itziar Rubio, Juan Manuel Mañé, Begoña Calvo, Unai Aresti, Aitziber Buque, Inés Marrodán, Alberto Muñoz

DOI: 10.4236/jct.2016.77047 1,888 Downloads 3,109 Views Citations

Pub. Date: June 27, 2016

Follow SCIRP